ProCE Banner Activity

HPTN 084 OLE: HIV-1 RNA Screening in Women Receiving Long-Acting Cabotegravir for PrEP

Conference Coverage
Slideset

In this open-label extension of the phase III HPTN 084 trial in women receiving LA CAB for PrEP, detection of HIV using single, isolated HIV-1 RNA tests was poor, with 75% of isolated positive HIV-1 RNA tests declared false positives.

Released: March 17, 2025

Expiration: September 16, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare